NewcelX Ltd.
NCEL Nasdaq Pharmaceutical Preparations Financials FY2018โFY2025
Revenue
Total sales reported in the income statement.
โ
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$8.3M
Free cash flow
Cash from operations minus capital spending.
โ$2.8M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ37.5%
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On $2.16 EPS (TTM)
What NewcelX Ltd. does
No business description yet.
- Legal name
- NewcelX Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Apr 29, 2026
- Accession ยท CIK
- 0001213900-26-049307
0001783036
Revenue and margins
NewcelX Ltd. had โ of revenue in fiscal 2025.
FY18
Revenue โ
FY19
Revenue โ
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue โ
FY18
Gross โ
Operating โ
Net โ
FCF โ
FY19
Gross โ
Operating โ
Net โ
FCF โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY18
Net income โ$5.1M
FY19
Net income โ$5.4M
FY20
Net income โ$2.9M
FY21
Net income โ$11.9M
FY22
Net income โ$16.5M
FY23
Net income โ$3.3M
FY24
Net income โ$7.2M
FY25
Net income โ$8.3M
FY18
Diluted EPS โ
FY19
Diluted EPS โ
FY20
Diluted EPS โ$0.41
FY21
Diluted EPS โ$1.00
FY22
Diluted EPS โ$33.52
FY23
Diluted EPS $1.13
FY24
Diluted EPS $2.43
FY25
Diluted EPS $2.16
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY18
Return on capital โ
Return on equity โ
Return on assets โ
FY19
Return on capital โ
Return on equity โ
Return on assets โ782.2%
FY20
Return on capital โ
Return on equity โ
Return on assets โ299.9%
FY21
Return on capital โ
Return on equity โ
Return on assets โ342.5%
FY22
Return on capital โ
Return on equity โ5,049.2%
Return on assets โ219.3%
FY23
Return on capital โ
Return on equity โ
Return on assets โ59.9%
FY24
Return on capital โ
Return on equity โ
Return on assets โ523.5%
FY25
Return on capital โ37.5%
Return on equity โ
Return on assets โ134.4%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$2.8M in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY18
Free cash flow โ
FY19
Free cash flow โ
FY20
Free cash flow โ
FY21
Free cash flow โ$15.0M
FY22
Free cash flow โ
FY23
Free cash flow โ$3.5M
FY24
Free cash flow โ$1.1M
FY25
Free cash flow โ$2.8M
FY18
Cash from operations โ$2.7M
Capital spending โ
FY19
Cash from operations โ$0.2M
Capital spending โ
FY20
Cash from operations โ$0.7M
Capital spending โ
FY21
Cash from operations โ$14.9M
Capital spending $0.0M
FY22
Cash from operations โ$13.9M
Capital spending โ
FY23
Cash from operations โ$3.4M
Capital spending $0.0M
FY24
Cash from operations โ$1.1M
Capital spending $0.0M
FY25
Cash from operations โ$2.8M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
NewcelX Ltd. returned โ to shareholders in fiscal 2025. The diluted share count rose 29.9%.
FY18
Dividends โ
Buybacks โ
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY18
Diluted shares 0.01B
FY19
Diluted shares 0.01B
FY20
Diluted shares 0.01B
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Balance sheet
Cash, debt and the ratios that show how comfortably NewcelX Ltd. can carry it.
FY18
Cash $0.0M
Debt โ
FY19
Cash $0.2M
Debt โ
FY20
Cash $0.1M
Debt $0.3M
FY21
Cash $5.4M
Debt โ
FY22
Cash $8.9M
Debt โ
FY23
Cash $1.1M
Debt โ
FY24
Cash $0.7M
Debt $7.7M
FY25
Cash $2.2M
Debt $0.4M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.4M | $8.9M | $1.1M | $0.7M | $2.2M |
| Debt incl. finance leases | โ | โ | โ | $7.7M | $0.4M |
| Debt / equity | โ | โ | โ | โ | 0.0x |
| Interest coverage | โ246.6x | โ162.6x | โ25.1x | โ45.8x | โ |
| Current ratio | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Quick ratio | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Total assets | $5.8M | $9.3M | $1.8M | $0.9M | $11.4M |
| Total liabilities | $5.2M | $6.0M | $10.7M | $8.9M | $4.2M |
| Shareholders' equity | $0.5M | $0.1M | โ$1.2M | โ$8.0M | $7.3M |
| Net debt (โ = net cash) | โ | โ | โ | $7.1M | โ$1.8M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 4 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | 4 / 7 |
| Accruals ratio | โ | โ754.9% | โ223.5% | 85.7% | โ34.8% | 2.0% | โ446.0% | โ89.6% |
| Altman Z'' | โ | โ201.77 | โ131.69 | โ33.52 | โ27.49 | โ156.99 | โ351.81 | โ24.45 |
8 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | $0.7M | $0.9M | $0.1M | $5.9M | $9.0M | $1.6M | $1.0M | $1.1M |
| Operating income | โ$3.4M | โ$4.2M | โ$2.3M | โ$11.9M | โ$15.5M | โ$3.0M | โ$2.1M | โ$2.6M |
| Interest expense | โ | $0.0M | $0.1M | $0.0M | $0.1M | $0.1M | $0.0M | โ |
| Pretax income | โ | โ | โ | โ | โ | โ$3.3M | โ$7.2M | โ |
| Net income | โ$5.1M | โ$5.4M | โ$2.9M | โ$11.9M | โ$16.5M | โ$3.3M | โ$7.2M | โ$8.3M |
| Net income to common | โ | โ | โ | โ | โ$16.5M | $3.3M | $7.2M | $8.3M |
| Diluted EPS | โ | โ | โ$0.41 | โ$1.00 | โ$33.52 | $1.13 | $2.43 | $2.16 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||
| Cash from operations | โ$2.7M | โ$0.2M | โ$0.7M | โ$14.9M | โ$13.9M | โ$3.4M | โ$1.1M | โ$2.8M |
| Capital expenditure | โ | โ | โ | $0.0M | โ | $0.0M | $0.0M | $0.0M |
| Free cash flow | โ | โ | โ | โ$15.0M | โ | โ$3.5M | โ$1.1M | โ$2.8M |
| Depreciation and amortization | โ | โ | โ | $0.0M | $0.0M | $0.6M | $0.4M | $0.1M |
| Stock-based compensation | โ | โ | โ | โ | $0.0M | $0.1M | $0.2M | $0.8M |
| Acquisitions | โ | โ | โ | โ | โ | โ | โ | โ$1.7M |
| Balance sheet | ||||||||
| Cash and short-term investments | $0.0M | $0.2M | $0.1M | $5.4M | $8.9M | $1.1M | $0.7M | $2.2M |
| Total debt | โ | โ | $0.3M | โ | โ | โ | $7.7M | $0.4M |
| Current assets | โ | $0.4M | $0.2M | $5.7M | $9.2M | $1.8M | $0.8M | $3.2M |
| Current liabilities | โ | $4.0M | $7.2M | $2.4M | $3.4M | $7.9M | $8.9M | $4.2M |
| Property and equipment, net | โ | โ | โ | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M |
| Goodwill | โ | โ | โ | โ | โ | โ | โ | $1.7M |
| Total assets | โ | $0.7M | $1.2M | $5.8M | $9.3M | $1.8M | $0.9M | $11.4M |
| Total liabilities | โ | $6.9M | $10.2M | $5.2M | $6.0M | $10.7M | $8.9M | $4.2M |
| Preferred stock | โ | โ | โ | โ | โ | โ | $2.7M | โ |
| Shareholders' equity | โ$8.8M | โ$6.2M | โ$9.0M | $0.5M | $0.1M | โ$1.2M | โ$8.0M | $7.3M |
| Returns | ||||||||
| Return on capital | โ | โ | โ | โ | โ | โ | โ | โ37.5% |
| Return on capital employed | โ | 125.7% | 38.4% | โ352.9% | โ261.7% | 49.6% | 25.8% | โ35.3% |
| Return on equity | โ | โ | โ | โ | โ5,049.2% | โ | โ | โ |
| Return on assets | โ | โ782.2% | โ299.9% | โ342.5% | โ219.3% | โ59.9% | โ523.5% | โ134.4% |
| Return on tangible equity | โ | โ | โ | โ2,202.5% | โ14,861.0% | โ | โ | 150.4% |
| Growth | ||||||||
| EPS growth | โ | โ | โ | โ | โ | โ | 115.0% | โ11.1% |
| Share count change | โ | 9.6% | 1.8% | 71.0% | โ95.9% | 500.5% | 0.1% | 29.9% |
| Financial health | ||||||||
| Debt / equity | โ | โ | โ | โ | โ | โ | โ | 0.0x |
| Interest coverage | โ | โ4,197.0x | โ26.5x | โ246.6x | โ162.6x | โ25.1x | โ45.8x | โ |
| Current ratio | โ | 0.1x | 0.0x | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Quick ratio | โ | 0.1x | 0.0x | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Quality scores | ||||||||
| Piotroski F-score | โ | โ | โ | โ | โ | โ | โ | 4.0 |
| Altman Z'' | โ | โ201.8 | โ131.7 | โ33.5 | โ27.5 | โ157.0 | โ351.8 | โ24.5 |
| Accruals ratio | โ | โ754.9% | โ223.5% | 85.7% | โ34.8% | 2.0% | โ446.0% | โ89.6% |
Source: SEC EDGAR XBRL filings (CIK 0001783036). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.